Oluranti Aladesanmi, MD
Internal Medicine · Holly Springs, GANPI 1891899449
Payments from drug & device makers
Across 104 payments — averaging $21.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$719
- Lilly USA, LLC$196
- Amgen$158
- Abbott$127
- Dexcom, Inc.$124
- Bayer$122
- plus $789 from 22 others
What the payments were for
- Food & beverage$2,234100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $719 |
| Lilly USA, LLC | 6 | $196 |
| Amgen(2 entities) | 8 | $158 |
| Abbott | 6 | $127 |
| Dexcom, Inc. | 8 | $124 |
| Bayer | 1 | $122 |
| AbbVie(2 entities) | 7 | $102 |
| Medtronic(2 entities) | 4 | $81 |
| Cequr Corporation | 1 | $76 |
| Boehringer Ingelheim | 4 | $68 |
| Mannkind Corporation | 2 | $43 |
| Harmony Biosciences LLC | 2 | $42 |
| Radius Health, Inc. | 3 | $40 |
| Amneal Pharmaceuticals LLC | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Johnson & Johnson | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Antares Pharma, Inc. | 1 | $19 |
| AstraZeneca | 1 | $19 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
| IBSA Pharma Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Merck | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,234 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 32 | $48,567 |
| TrulicityDulaglutide | 21 | $25,614 |
| MounjaroTirzepatide | 15 | $18,289 |
| JardianceEmpagliflozin | 16 | $15,607 |
| OzempicSemaglutide | 12 | $13,190 |
| RybelsusSemaglutide | 13 | $12,239 |
| FarxigaDapagliflozin Propanediol | 14 | $11,395 |
| XareltoRivaroxaban | 13 | $10,482 |
| BelsomraSuvorexant | 12 | $5,343 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $3,942 |
| Gabapentin | 208 | $3,440 |
| Atorvastatin Calcium | 495 | $3,390 |
| SynthroidLevothyroxine Sodium | 34 | $2,493 |
| Losartan Potassium | 295 | $2,435 |
| Levothyroxine Sodium | 195 | $2,153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $14 | $49,99659 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $196 | $43,90336 claims |
| Novo NordiskOzempic, Rybelsus | $719 | $25,42925 claims |
| Boehringer IngelheimJardiance | $68 | $15,60716 claims |
| AstraZenecaFarxiga | $19 | $11,39514 claims |
| Johnson & JohnsonXarelto | $30 | $10,48213 claims |
| MerckBelsomra | $17 | $5,34312 claims |
| AbbVieSynthroid | $102 | $2,49334 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $36 | $2,153195 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Holly Springs
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.